NCT06342713 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases | Biotech Hunter

Enrollment

211

Participants

Timeline

Start Date

June 3, 2024

Primary Completion Date

May 23, 2026

Study Completion Date

May 23, 2026

Conditions

Healthy ParticipantsHealthy SubjectsHealthy VolunteersAutoimmune DiseasesHealthy Adult ParticipantsAtopic DermatitisPrurigo Nodularis

Interventions

DRUG

BGB-45035

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (12)

1010

RECRUITING

Optimal Clinical Trials Ltd, Auckland

5018

RECRUITING

Lakeland Clinical Trials Wellington, Upper Hutt

100000

RECRUITING

Peking University Third Hospital, Beijing

110001

RECRUITING

The First Hospital of China Medical University, Shenyang

266555

RECRUITING

The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao

410008

RECRUITING

Xiangya Hospital of Central South University, Changsha

610021

RECRUITING

Chengdu Second Peoples Hospital, Chengdu

630014

RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

NSW 2077

RECRUITING

Innovate Clinical Research, Waitara

SA 5000

RECRUITING

Cmax Clinical Research, Adelaide

Unknown

NOT_YET_RECRUITING

Dermatology Hospital of Southern Medical University, Guangzhou

0622

RECRUITING

Pacific Clinical Research Network Auckland, Takapuna